hydroxyurea has been researched along with Neurofibromatosis 2 in 1 studies
Neurofibromatosis 2: An autosomal dominant disorder characterized by a high incidence of bilateral acoustic neuromas as well as schwannomas (NEURILEMMOMA) of other cranial and peripheral nerves, and other benign intracranial tumors including meningiomas, ependymomas, spinal neurofibromas, and gliomas. The disease has been linked to mutations of the NF2 gene (GENES, NEUROFIBROMATOSIS 2) on chromosome 22 (22q12) and usually presents clinically in the first or second decade of life.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sathornsumetee, S | 1 |
| DesJardins, A | 1 |
| Reardon, DA | 1 |
| Rich, JN | 1 |
| Vredenburgh, JJ | 1 |
1 other study available for hydroxyurea and Neurofibromatosis 2
| Article | Year |
|---|---|
Neurofibromatosis type 2.
Topics: Antineoplastic Agents; Benzamides; Cochlear Nerve; Female; Functional Laterality; Hearing Loss, Sens | 2007 |